<DOC>
	<DOCNO>NCT00025311</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness intrathecal intraventricular topotecan treating recurrent , progressive , refractory cancer metastatic lining around brain .</brief_summary>
	<brief_title>Topotecan Treating Patients With Recurrent , Progressive , Refractory Cancer That Metastatic Lining Around Brain</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose intrathecal intraventricular topotecan patient recurrent , progressive , refractory leptomeningeal disease . - Determine toxicity regimen patient . - Determine pharmacokinetics regimen patient . - Determine anti-tumor activity regimen patient . OUTLINE : This dose-escalation study . Patients stratify accord disease ( leukemia lymphoma v solid tumor malignancy ) . Patients receive topotecan intrathecally intraventricularly continuously day 1-7 . Treatment repeat every 21 day 7 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose- limiting toxicity . Patients follow 6 month . PROJECTED ACCRUAL : A maximum 50 patient ( 25 per stratum ) accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic tumor marker confirmation malignancy original diagnosis Neoplastic meningitis/leptomeningeal metastasis refractory conventional therapy therapy higher priority , define : Stratum A : Small noncleaved lymphoma ( Burkitt 's ) L3 blast cerebrospinal fluid ( CSF ) Any lymphoma leukemia CSF cell count great 5/mm3 AND evidence blast cell cytology cytospin preparation OR Stratum B : Solid tumor malignancy presence tumor cell cytospin OR positive cytology OR neuroimaging evidence leptomeningeal tumor MRI CT myelogram No leptomeningeal leukemia lymphoma concurrent bone marrow relapse No clinical evidence untreated obstructive hydrocephalus compartmentalization CSF PATIENT CHARACTERISTICS : Age : 65 Performance status : Lansky 50100 % ( age 16 ) Karnofsky 50100 % OR ECOG 03 ( age 16 ) Life expectancy : At least 2 month Hematopoietic : Stratum B : Absolute neutrophil count least 750/mm^3 Platelet count least 75,000/mm^3 ( transfusion independent ) Hemoglobin least 10.0 g/dL ( red blood cell transfusion allow ) Hepatic : Bilirubin great 1.5 time normal SGOT SGPT less 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Neurologic : Seizures allow well controlled anticonvulsant CNS toxicity great grade 2 Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection HIV allow PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunomodulating agent ( stratum B ) No stem cell transplantation ( stratum A ) Chemotherapy : At least 2 week since prior chemotherapy ( 4 week nitrosoureas ) No concurrent cancer chemotherapy ( stratum B ) Other concurrent systemic cancer chemotherapy leukemia lymphoma allow follow restriction : No oral IV topotecan No moderate highdose IV subcutaneous cytarabine ( great 1.0 g/m2 per day ) No moderate highdose IV methotrexate ( great 1 g/m2 per day ) No IV thiotepa No myeloablative chemotherapy No intrathecal intraventricular chemotherapy Endocrine therapy : Concurrent corticosteroid allow treatment increase intracranial pressure patient CNS tumors No concurrent intrathecal intraventricular hydrocortisone Radiotherapy : At least 4 week since completion radiotherapy brain spine recover Concurrent radiotherapy localize painful lesion produce acute neurologic dysfunction allow provide least 1 measurable lesion irradiate No concurrent craniospinal wholebrain radiotherapy Surgery : Not specify Other : Recovered prior therapy At least 7 day since prior investigational drug No concurrent intrathecal intraventricular therapy leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>leptomeningeal metastasis</keyword>
</DOC>